COLL
Collegium Pharmaceutical Inc
22.60$
+0.8%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -0.9% | -15.5% | +8.8% | -113.4% | – | -34.6% | +30.8% | +8.3% | +56.9% | -53.6% | +24.9% | – | |
| – | -4.5% | -0.1% | +0.1% | +17.7% | +35.4% | +0.1% | +0.1% | -0.2% | +5.2% | -7.0% | +18.3% | – | |
| – | -0.4% | +6.8% | +33.9% | -26.9% | +3.8% | +51.7% | -6.1% | -9.3% | -0.6% | +11.6% | +33.1% | – | |
| – | -123.8% | – | – | – | – | -193.4% | – | – | – | -170.5% | – | – | |
| – | +152.3% | +246.3% | -52.5% | -9.6% | +133.6% | +40.0% | -91.9% | +189.2% | +266.5% | -60.8% | +83.7% | – | |
| – | +556.6% | -27.8% | -50.9% | +2,695.5% | -95.3% | -17.7% | -69.9% | +958.9% | -35.0% | – | -30,990.7% | – | |
| – | -85.7% | – | – | – | – | – | – | – | – | – | – | – | |
| – | -50.0% | -48.5% | +171.9% | -99.6% | +17,523.2% | – | -5,061.3% | – | -198.6% | – | – | – | |
| – | – | – | – | – | -110.9% | +0.0% | +0.0% | +0.0% | +35.9% | -67.0% | – | – | |
| – | -28.9% | -20.2% | +110.9% | – | -127.7% | -38.9% | +91.7% | -69.4% | +47.3% | -2.2% | – | – | |
| – | – | – | – | – | – | -35.2% | +3.3% | +54.8% | +147.8% | -53.9% | -472.2% | – | |
| – | -1.1% | -16.1% | +9.4% | -113.8% | – | -35.1% | +32.6% | +8.1% | +56.4% | -53.5% | +24.6% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.